Recent Updates
Recently added Catalysts

Hyperbaric oxygen

Phase 2

Traumatic Brain Injury | Small molecule | Neurology |National Healthcare Corp.|Last Updated: Jun 2, 2026

Target and mechanism

ModalitySmall molecule

Also known as Hyperbaric oxygen (1.5 ATA, no NBH)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment200

FDA Designations

No designations recorded

Clinical trial landscape

Hyperbaric oxygen · 1 trial · 1 indication

Phase 2 1
NCT02407028Hyperbaric Oxygen Brain Injury Treatment TrialTraumatic Brain Injury
RECRUITING200 Analytics
PHASE2RECRUITING
Hyperbaric Oxygen Brain Injury Treatment Trial
Traumatic Brain InjuryUnlock trial analytics

Study Endpoints

Primary Endpoints

Glasgow Outcome Scale Extended (GOS-E)
Assessment at 6 months

Secondary Endpoints

Duration of ICP elevation
First 5 days
Therapeutic intensity level scores for controlling intracranial pressure (ICP)
First 5 days
Brain tissue partial pressure of oxygen
First 5 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelFACTORIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Hyperbaric oxygen (1.5 ATA, no NBH)EXPERIMENTALHyperbaric oxygen at 1.5 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
Hyperbaric oxygen (2.0 ATA, no NBH)EXPERIMENTALHyperbaric oxygen at 2.0 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
Hyperbaric oxygen (2.5 ATA, no NBH)EXPERIMENTALHyperbaric oxygen at 2.5 ATA for 1 hour, without NBH. This treatment is administered twice a day for 5 days.
Hyperbaric oxygen (1.5 ATA + NBH)EXPERIMENTALHyperbaric oxygen at 1.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
Hyperbaric oxygen (2.0 ATA + NBH)EXPERIMENTALHyperbaric oxygen at 2.0 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
Hyperbaric oxygen (2.5 ATA + NBH)EXPERIMENTALHyperbaric oxygen at 2.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
Normobaric Hyperoxia (NBH)EXPERIMENTALNormobaric Hyperoxia (NBH meaning 100% O2 at 1.0 ATA) for 4.5 hours twice a day for 5 days.
Usual careACTIVE_COMPARATORUsual care for severe TBI

Interventions

NameTypeDescription
Hyperbaric oxygen (1.5 ATA, no NBH)DRUGHBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
Hyperbaric oxygen (2.0 ATA, no NBH)DRUGHBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
Hyperbaric oxygen (2.5 ATA, no NBH)DRUGHBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
Hyperbaric oxygen (1.5 ATA + NBH)DRUGHBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
Hyperbaric oxygen (2.0 ATA + NBH)DRUGHBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
Hyperbaric oxygen (2.5 ATA + NBH)DRUGHBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
Normobaric Hyperoxia (NBH)DRUG100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
Usual CareOTHERWill be treated with usual and customary care for severe traumatic brain injury
Unlock Study Design Details

Eligibility Criteria

Age Range16 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria: * Age 16 years or older and 65 years or younger * Present with severe TBI, defined as Glasgow Coma Scale (GCS) of 3 to 8. * Marshall computerized tomography (CT) score \>1 in patients with a GCS of 7 or 8 or patients with an alcohol level \>200 mg/dl * Ability to initiate the fi...

Countries:United StatesCanada
Unlock Eligibility Criteria

Frequently asked questions about Hyperbaric oxygen

What is Hyperbaric oxygen used for in Traumatic Brain Injury?

Hyperbaric oxygen is being studied as a treatment for Traumatic Brain Injury. It is currently in Phase 2 clinical development as an investigational therapy. The treatment involves administering oxygen at increased atmospheric pressure, and it is being evaluated for its potential to improve outcomes in patients with this condition.

What does Hyperbaric oxygen target?

Hyperbaric oxygen does not target a specific molecular receptor or pathway. Instead, it works by delivering increased oxygen levels to tissues under elevated atmospheric pressure, which may help reduce brain injury and promote recovery after trauma. This mechanism is being investigated in the context of Traumatic Brain Injury.

Who makes Hyperbaric oxygen?

Hyperbaric oxygen is being developed by National Healthcare Corp., a company traded under the ticker symbol NHC. The company is conducting clinical research to evaluate the therapy's safety and efficacy for Traumatic Brain Injury.

What phase is Hyperbaric oxygen in?

Hyperbaric oxygen is currently in Phase 2 clinical trials. It is an investigational therapy, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 2 study is designed to assess its effects in patients with Traumatic Brain Injury.

What clinical trials is Hyperbaric oxygen in?

Hyperbaric oxygen is being evaluated in one active Phase 2 clinical trial, identified as NCT02407028, titled 'Hyperbaric Oxygen Brain Injury Treatment Trial.' This randomized, active-controlled study is recruiting 200 participants with Traumatic Brain Injury at sites in the United States and Canada.

Is Hyperbaric oxygen the same as Hyperbaric oxygen (1.5 ATA, no NBH)?

Yes, Hyperbaric oxygen is also known as Hyperbaric oxygen (1.5 ATA, no NBH). The alternative name specifies the treatment protocol, which involves administering oxygen at 1.5 atmospheres absolute without the use of normobaric hyperoxia. Both names refer to the same investigational therapy.